Clinical-stage biopharmaceutical company Cellectis announced the issuance of two US patents “for the invention of certain uses of RNA-guided endonucleases, such as Cas9 or Cpf1, for the genetic engineering of T-cells.”
Cellectis said: “Both patents claim methods by which T-cells are gene edited using transient expression of CRISPR/Cas9 components.
“These inventions are based on the early work initiated by inventors at Cellectis when the CRISPR technology first came to light.”
CRISPR is an abbreviation of Clustered Regularly Interspaced Short Palindromic Repeats and forms the basis of techniques known as CRISPR/Cas9 or Cpf1 that modify the structures of genes within living organisms.
CRISPR/Cas9 works like a pair of molecular scissors that can selectively trim away unwanted parts of the genome and replace it with new stretches of DNA.
Cellectis Chairman & CEO André Choulika said: “Cellectis is a pioneering gene editing company that has always been keen to be at the forefront of all gene editing technologies.
“We have been the first to explore the potential of CRISPR in its early days in various applications, including therapeutics and plants.
“These early findings ultimately led to the grant of this set of new patents. As such, these patents only reinforce Cellectis’ leadership position in the gene editing industry.”